ubiI Antibody

What is Ubiquilin-2 and why are antibodies against it important for research?

Ubiquilin-2 (UBQLN2) is a member of the ubiquilin protein family that plays a critical role in regulating protein degradation pathways in cells. The protein contains an N-terminal ubiquitin-like (UBL) domain and a C-terminal ubiquitin-associated (UBA) domain, while the central region shows high variability. Ubiquilin-2 physically associates with both proteasomes and ubiquitin ligases, functionally linking the ubiquitination machinery to the proteasome to affect in vivo protein degradation .

Research interest in Ubiquilin-2 has intensified since discoveries by Teepu Siddique and collaborators identified mutations in the ubiquilin-2 gene contributing to amyotrophic lateral sclerosis (ALS) and Frontotemporal lobar degeneration (FTLD). Particularly significant are mutations involving proline residues in the PXX repeat region (P497H, P497S, P506T, P509S, and P525S) . Recent investigations have also revealed distinct Ubiquilin-2 pathology in ALS and FTLD-TDP patients with C9orf72 expansion .

Antibodies against Ubiquilin-2 are therefore crucial research tools for:

• Investigating neurodegenerative disease mechanisms

• Studying protein quality control pathways

• Examining proteasomal degradation systems

• Analyzing disease-related protein aggregation patterns

What methodological approaches should be used to validate Ubiquilin-2 antibodies?

Proper validation of Ubiquilin-2 antibodies requires a systematic approach using knockout controls. The most rigorous validation methodology involves:

• Knockout validation strategy: Compare antibody performance in knockout cell lines versus isogenic parental controls using standardized experimental protocols .

• Mosaic cell plating technique: Plate wild-type and knockout cells together in the same well and image both cell types in the same field of view to reduce staining, imaging and image analysis biases .

• Multi-application testing: Characterize antibody performance across multiple applications including Western Blot, immunoprecipitation, and immunofluorescence .

• Cross-species reactivity assessment: Test antibody performance across multiple species when possible. For example, Proteintech's Mouse Monoclonal Ubiquilin-2 antibody (60495-1-Ig) has demonstrated reactivity with human, rat, pig, and rabbit samples .

This validation approach ensures that observed signals genuinely represent Ubiquilin-2 rather than non-specific binding or cross-reactivity with other proteins.

What are the optimal conditions for using Ubiquilin-2 antibodies in Western blotting?

For optimal Western blotting results with Ubiquilin-2 antibodies, researchers should consider the following methodological parameters:

Dilution optimization:

• Recommended dilution ranges for Ubiquilin-2 antibodies in Western blotting typically fall between 1:5000-1:50000 .

• Titration experiments in your specific system are recommended to determine optimal concentration.

Sample preparation considerations:

• Successful detection has been reported in multiple cell types including HEK-293, A431, LNCaP, HeLa, and MOLT-4 cells.

• For tissue samples, positive results have been achieved in pig, rabbit, and rat brain tissues .

Expected molecular weight:

• Ubiquilin-2 has a calculated molecular weight of 66 kDa (624 amino acids) .

• The observed molecular weight in Western blot matches this prediction at approximately 66 kDa.

Storage and handling:

• Store antibodies according to manufacturer recommendations, typically at -20°C for antibodies in storage buffer containing glycerol.

• For antibodies in PBS only, storage at -80°C is recommended .

How should immunofluorescence protocols be optimized for Ubiquilin-2 detection?

For reproducible and specific immunofluorescence detection of Ubiquilin-2, the following methodological approach is recommended:

Fixation protocol:

• Fix cells in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) for 15 minutes at room temperature.

• Wash three times with PBS following fixation .

Permeabilization conditions:

• Permeabilize cells in PBS with 0.1% Triton X-100 for 10 minutes at room temperature.

• Block with PBS containing 5% BSA, 5% goat serum, and 0.01% Triton X-100 for 30 minutes at room temperature .

Antibody incubation parameters:

• Dilute primary Ubiquilin-2 antibodies in IF buffer (PBS, 5% BSA, 0.01% Triton X-100) at 1:200-1:800 dilution.

• Incubate with primary antibody overnight at 4°C.

• Wash 3 × 10 minutes with IF buffer.

• Incubate with corresponding Alexa Fluor-conjugated secondary antibodies at a dilution of 1.0 μg/ml for 1 hour at room temperature with DAPI .

Validation controls:

• Include wild-type and knockout cells as positive and negative controls.

• Consider using the mosaic plating strategy to compare signal in both cell types within the same field of view .

How can antibodies be developed for site-specific ubiquitin modifications?

Developing antibodies against site-specific ubiquitin modifications requires sophisticated chemical synthesis approaches:

Antigen design strategy:

• Synthesize full-length ubiquitin and derivatives that can be attached to target peptides.

• Apply chemical ligation technologies that allow synthesis of well-defined Ub-modified polypeptides, either with:

  • Native isopeptide linkage using thiolysine mediated ligation

  • Proteolytically stable bond using click chemistry (which replaces the native isopeptide bond with a proteolytically stable amide triazole isostere) .

Immunization and screening methodology:

• Design and synthesize non-hydrolyzable Ub-peptide conjugates (15-17 amino acids with central modification) for immunization.

• Prepare extended native iso-peptide linked Ub-peptide conjugates for screening.

• For peptides corresponding to internal sequences:

  • Acetylate the N-terminus to eliminate positively charged N-terminal amino groups

  • Amidate the C-terminus .

• ELISA screens should use native iso-peptide linked Ub-polypeptides that are two amino acids longer at the N-terminus and/or C-terminus than the immunization antigen to better mimic the native protein .

This approach has been successfully applied to develop antibodies against site-specific ubiquitination of histone H2B and could be adapted for other ubiquitinated targets.

What methodological considerations apply when investigating the interplay between Ubiquilin-2 and protein degradation pathways?

When studying how Ubiquilin-2 functions in protein degradation pathways, researchers should consider these methodological approaches:

Receptor ligation chase model:

• This model can determine the molecular signature of ubiquitination and degradation of proteins mediated through the ubiquitin-proteasome system .

Knockout validation system:

• USP13 knockout models have revealed how deubiquitinating enzymes can affect protein stability in the ubiquitin-proteasome system .

• A similar approach could elucidate how Ubiquilin-2 links ubiquitinated substrates to the proteasome.

Proteasome inhibition studies:

• Treating cells with proteasome inhibitors while monitoring Ubiquilin-2 interactions can help determine whether observed effects are mediated through proteasomal degradation.

Co-immunoprecipitation experiments:

• Since Ubiquilin-2 physically associates with both proteasomes and ubiquitin ligases, co-immunoprecipitation using Ubiquilin-2 antibodies can identify interaction partners under different cellular conditions .

How can Ubiquilin-2 antibodies be applied to neurodegenerative disease research?

Ubiquilin-2 antibodies provide valuable tools for investigating neurodegenerative disease mechanisms through several methodological approaches:

Pathological aggregation analysis:

• Immunohistochemistry using Ubiquilin-2 antibodies can detect pathological inclusions in patient tissues and animal models.

• The Lee and Trojanowski group employed this approach to identify distinct Ubiquilin-2 pathology in ALS and FTLD-TDP patients with C9orf72 expansion .

Mutation-specific studies:

• Antibodies can be used to examine the cellular behavior of Ubiquilin-2 variants containing disease-associated mutations (P497H, P497S, P506T, P509S, and P525S).

• Immunofluorescence can reveal differences in subcellular localization between wild-type and mutant forms.

Protein-protein interaction changes:

• Co-immunoprecipitation using Ubiquilin-2 antibodies can identify whether disease-associated mutations alter interactions with the proteasome or ubiquitin ligases.

What considerations are important when interpreting Ubiquilin-2 antibody results in the context of therapeutic development?

When using Ubiquilin-2 antibodies to evaluate potential therapeutic approaches, researchers should consider:

Baseline expression variability:

• Control for variations in Ubiquilin-2 expression levels between tissues, cell types, and disease states.

• The observed molecular weight of 66 kDa should be consistent across experimental systems .

Cross-reactivity assessment:

• Ensure antibodies do not cross-react with other ubiquilin family members (Ubiquilin-1, 3, and 4) .

• All ubiquilins contain UBL and UBA domains, but differ in their central regions.

Drug-induced changes:

• When evaluating therapeutic candidates, consider whether drugs might alter epitope accessibility rather than actual protein levels.

Therapeutic antibody development insights:

• The UB-312 vaccine development process provides a methodological framework for developing therapeutic antibodies against protein targets involved in neurodegenerative diseases.

• This approach demonstrated successful antibody production in both serum and CSF, with a CSF/serum ratio of approximately 0.2% .

How can researchers address specificity challenges with ubiquitin system antibodies?

When encountering specificity issues with antibodies targeting components of the ubiquitin system, consider these methodological approaches:

Knockout validation:

• Always validate antibody specificity using genetic knockout systems when possible.

• The approach used for Ubiquilin-2 antibody validation, comparing knockout cell lines with isogenic parental controls, represents the gold standard .

Epitope mapping:

• Determine which domain of Ubiquilin-2 is recognized by the antibody (UBL domain, UBA domain, or central region).

• Antibodies targeting the more variable central region may provide higher specificity against particular ubiquilin family members.

Cross-adsorption techniques:

• If cross-reactivity with other ubiquilin family members is observed, consider pre-adsorbing the antibody with recombinant proteins of the cross-reacting family members.

Antibody concentration optimization:

• Titrate antibody dilutions precisely for each application and cell/tissue type.

• Western blot applications typically require much higher dilutions (1:5000-1:50000) than immunofluorescence (1:200-1:800) .

What are the critical factors for reproducible results when using ubiquitin and ubiquilin antibodies?

To ensure reproducible results when working with antibodies in the ubiquitin system, researchers should address:

Antibody storage and handling:

• Follow manufacturer storage recommendations precisely.

• For glycerol-containing formulations, store at -20°C.

• For PBS-only formulations, store at -80°C .

• Aliquot antibodies to avoid repeated freeze-thaw cycles.

Sample preparation standardization:

• Standardize cell lysis and protein extraction protocols.

• Include protease inhibitors to prevent degradation during preparation.

• For ubiquitinated proteins, include deubiquitinase inhibitors in lysis buffers.

Validation across applications:

• An antibody that performs well in Western blot may not necessarily work for immunoprecipitation or immunofluorescence.

• Validate each antibody for your specific application using appropriate positive and negative controls .

Detailed protocol documentation:

• Record all experimental parameters including fixation times, permeabilization conditions, blocking formulations, antibody concentrations, and incubation times.

• Follow standardized protocols similar to those described for Ubiquilin-2 antibody characterization .